Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world tislelizumab use in recurrent or metastatic esophageal cancer in high-incidence regions of China
ChiCTR2400089404Phase 4Not yet recruiting
- Sponsor
- Gaozhou People's Hospital
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by Gaozhou People's Hospital. Primary endpoint: Progression-free survival in second-line treatment. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400089404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089404.